RxDoctor Payments Data

Amy Lundholm, DO

Rheumatology · Ridley Park, PANPI 1689901324

Payments from drug & device makers

$45,615in general payments, 2019–2025

Across 1,346 payments — averaging $33.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • Amgen$6K
  • GSK$5K
  • AstraZeneca$2K
  • UCB, Inc.$2K
  • Novartis$2K
  • plus $10K from 34 others

What the payments were for

  • Consulting fees$8,11618%
  • Speaking & faculty fees$8,80019%
  • Travel & lodging$1,4493%
  • Food & beverage$26,87059%
  • Education$3791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,615 in reported general payments places this provider in the 80th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,438,903
Medicare patients
657
Services billed
214,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab44$439,058
Enbrel SureclickEtanercept29$234,906
RinvoqUpadacitinib20$186,765
TymlosAbaloparatide48$126,919
Evenity (2 Syringes)Romosozumab-Aqqg42$103,745
ProliaDenosumab31$52,386
WegovySemaglutide25$33,056
OzempicSemaglutide11$10,250
Hydroxychloroquine Sulfate270$6,476
MethotrexateMethotrexate Sodium254$5,379
Pregabalin190$5,268
Colchicine14$1,801
Alendronate Sodium248$1,700
Gabapentin193$1,692
Prednisone228$1,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$17,798$186,76520 claims
AmgenEvenity (2 Syringes), Prolia$6,014$156,13173 claims
Radius Health, Inc.Tymlos$1,176$126,91948 claims
Novo NordiskWegovy, Ozempic$109$43,30636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Ridley Park

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →